Risk prediction models for patients with chronic kidney disease a systematic review

Annals of Internal Medicine

Volumn 158, Issue 8, 2013, Pages 596-603

  Tangri, Navdeep ^a   Kitsios, Georgios D ^c   Inker, Lesley Ann ^b   Griffith, John ^d   Naimark, David M ^e   Walker, Simon ^a   Rigatto, Claudio ^a   Uhlig, Katrin ^b   Kent, David M ^b   Levey, Andrew S ^b  

^a Seven Oaks General Hospital Winnipeg Manitoba   (Canada)

^b TUFTS MEDICAL CENTER   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CLASSIFICATION; COHORT ANALYSIS; CREATININE BLOOD LEVEL; EXTERNAL VALIDITY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INTERNAL VALIDITY; KIDNEY FAILURE; MEDLINE; MODEL; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, STATISTICAL; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84876396728     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-8-201304160-00004     Document Type: Review

References (42)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-305.
2. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, et al; Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941-51.
3. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al; Chronic Kidney Disease Prognosis Consortium. Lower esti-mated glomerular filtration rate and higher albuminuria are associated with mor-tality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79:1331-40.
4. Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al; Chronic Kidney Disease Prognosis Consortium. Lower esti-mated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93-104.
5. Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: a step forward [Editorial]. Ann Intern Med. 2011;154:65-7.
6. Taal MW, Brenner BM. Renal risk scores: progress and prospects. Kidney Int. 2008;73:1216-9.
7. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA. 2011;305:1553-9.
8. Oliver MJ, Quinn RR, Garg AX, Kim SJ, Wald R, Paterson JM. Likelihood of starting dialysis after incident fistula creation. Clin J Am Soc Nephrol. 2012; 7:466-71.
9. O'Hare AM, Choi AI, Bertenthal D, Bacchetti P, Garg AX, Kaufman JS, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007; 18:2758-65.
10. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for tradi-tional and novel measures. Epidemiology. 2010;21:128-38.
11. Bouwmeester W, Zuithoff NP, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Med. 2012;9:1-12.
12. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-72.
13. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144:427-37.
14. Dimitrov BD, Ruggenenti P, Stefanov R, Perna A, Remuzzi G. Chronic nephropathies: individual risk for progression to end-stage renal failure as pre-dicted by an integrated probabilistic model. Nephron Clin Pract. 2003;95:c47-59.
15. Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, et al; RENAAL Study Investigators. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2006;1:761-7.
16. Wakai K, Kawamura T, Endoh M, Kojima M, Tomino Y, Tamakoshi A, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800-8.
17. Johnson ES, Thorp ML, Platt RW, Smith DH. Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study.Am J Kidney Dis. 2008;52:653-60.
18. Goto M, Wakai K, Kawamura T, Ando M, Endoh M, Tomino Y. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year pro-spective cohort study. Nephrol Dial Transplant. 2009;24:3068-74.
19. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kid-ney Dis. 2010;56:1082-94.
20. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in pa-tients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis. 2011; 58:717-28.
21. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: compar-ison of traditional and novel risk factors. JAMA. 2005;293:1737-45.
22. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217-24.
23. McMurray JJ, Uno H, Jarolim P, Desai AS, de Zeeuw D, Eckardt KU, et al. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). Am Heart J. 2011;162:748-755.e3.
24. Johnson ES, Thorp ML, Yang X, Charansonney OL, Smith DH. Predicting renal replacement therapy and mortality in CKD. Am J Kidney Dis. 2007;50: 559-65.
25. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22:752-61.
26. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al; Na-tional Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-47.
27. Bitton A, Gaziano TA. The Framingham Heart Study's impact on global risk assessment. Prog Cardiovasc Dis. 2010;53:68-78.
28. Counsell C, Dennis M. Systematic review of prognostic models in patients with acute stroke. Cerebrovasc Dis. 2001;12:159-70.
29. Perel P, Edwards P, Wentz R, Roberts I. Systematic review of prognostic models in traumatic brain injury. BMC Med Inform Decis Mak. 2006;6:38.
30. Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, et al. Risk prediction models for hospital readmission: a systematic review. JAMA. 2011;306:1688-98.
31. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol. 2010;21:1086-92.
32. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-53.
33. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32.
34. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147:840-53.
35. Hemmelgarn BR, Zhang J, Manns BJ, James MT, Quinn RR, Ravani P, et al; Alberta Kidney Disease Network. Nephrology visits and health care re-source use before and after reporting estimated glomerular filtration rate. JAMA. 2010;303:1151-8.
36. Kagoma YK, Weir MA, Iansavichus AV, Hemmelgarn BR, Akbari A, Patel UD, et al. Impact of estimated GFR reporting on patients, clinicians, and health-care systems: a systematic review. Am J Kidney Dis. 2011;57:592-601.
37. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18:1959-65.
38. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. 2006;37:2957-62.
39. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol. 2011;22:147-55.
40. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxy-lated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152:640-8.
41. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Predic-tion Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180-7.
42. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost. 2011;106:528-38.